NCT07710898

Brief Summary

A common metabolic abnormality in hyperglycemic individuals, dyslipidemia is strongly linked to an increased risk of cardiovascular illness. This study looked at how date cider vinegar and 5:2 intermittent fasting affected the lipid profile and metabolic indices of hyperglycemic patients

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
108

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jan 2026

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 12, 2026

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 12, 2026

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

May 12, 2026

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

July 14, 2026

Completed
3 days until next milestone

First Posted

Study publicly available on registry

July 17, 2026

Completed
Last Updated

July 17, 2026

Status Verified

January 1, 2026

Enrollment Period

3 months

First QC Date

July 14, 2026

Last Update Submit

July 14, 2026

Conditions

Keywords

Diabete MellitusPrediabetesHyperlipidemialipid profiledate- cider vinegar

Outcome Measures

Primary Outcomes (1)

  • Body Mass Index

    BMI was calculated by dividing weight (in kg) by the square of height (in meters).

    3 months

Secondary Outcomes (2)

  • Blood pressure

    3 months

  • Lipid Profile

    3 months

Study Arms (3)

Control Group (T 0 )

ACTIVE COMPARATOR

Participants continued their prescribed conventional medications for hyperglycemia and lipid management without any additional dietary or vinegar intervention for a duration of 3 months.

Drug: Control Group (T 0 )

Experimental Group (T 1 )

EXPERIMENTAL

Participants received Date Cider Vinegar (DCV) for a duration of 3 months.

Dietary Supplement: Experimental Group (T 1 )

Experimental Group (T 2 )

EXPERIMENTAL

Participants followed 5:2 Intermittent Fasting (two non-consecutive fasting days per week) along with DCV intervention for a duration of 3 months.

Combination Product: Experimental Group (T 2 )

Interventions

The control group received standard dietary advice without vinegar supplementation or fasting intervention.

Control Group (T 0 )
Experimental Group (T 1 )DIETARY_SUPPLEMENT

Participants were advised to take 15 ml of Date Cider Vinegar (DCV) diluted in 1 cup (250ml) of water 15 minutes before breakfast and dinner daily for a duration of 3 months.

Experimental Group (T 1 )
Experimental Group (T 2 )COMBINATION_PRODUCT

Participants were advised to follow 5:2 Intermittent Fasting (two non-consecutive fasting days per week) along with DCV intervention for a duration of 3 months. 15 ml of DCV was diluted in 1 cup of water and It was taken 15 minutes before breakfast and dinner daily.

Experimental Group (T 2 )

Eligibility Criteria

Age35 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adults with a diagnosis of mild to moderate hypertension
  • Mild hypertension (140-159/90-99 mm Hg)
  • Moderate hypertension (160-179/100-109 mm Hg)
  • Adults having mild to moderate alterations in lipid profile
  • Triglycerides: 150 to 499 mg/dL
  • LDL-C levels: Mild Alteration (130 to 159 mg/dL) and Moderate Alteration (160 to 189 mg/dL)
  • Adults with pre-diabetes (hbA1c= 5.6-6.4%) were used.
  • Patients were solicited from hospital.

You may not qualify if:

  • Any Lactating and pregnant women were not included.
  • Any person allergic to citric acid.
  • Adults suffering from critical health conditions, including cancer.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The University of Lahore

Lahore, Pakistan

Location

Related Links

MeSH Terms

Conditions

Diabetes MellitusPrediabetic StateHyperlipidemias

Interventions

Control Groups

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesDyslipidemiasLipid Metabolism Disorders

Intervention Hierarchy (Ancestors)

Epidemiologic Research DesignEpidemiologic MethodsInvestigative TechniquesResearch DesignMethods

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Head

Study Record Dates

First Submitted

July 14, 2026

First Posted

July 17, 2026

Study Start

January 12, 2026

Primary Completion

April 12, 2026

Study Completion

May 12, 2026

Last Updated

July 17, 2026

Record last verified: 2026-01

Locations